Intended for US Healthcare Professionals Only.

ON-DEMAND WEBINAR

Final Results From the NUWIQ® PUP Study

Improving Treatment Decisions
With the 8CHECK Gene Mutation Testing Service

View On-Demand Webinar

On-Demand Webinar: Final Results From the NUWIQ PUP Study

Improving Treatment Decisions With the 8CHECK Gene Mutation Testing Service


Presented By:

Final Results from the NUWIQ PUP Study

Ellis J. Neufeld, MD, PhD

Clinical Director and Executive Vice President
John and Lorine Thrasher Endowed Chair
St. Jude Children's Research Hospital

Dr. Neufeld will share final results from the landmark NuProtect study—the largest prospective clinical trial with a single FVIII product in previously untreated patients (PUPs) with hemophilia A completed to date. The completion of this study is a major milestone for NUWIQ and the hemophilia community.

Improving Treament Decisions With the 8CHECK Gene Mutation Service

Barbara A. Konkle, MD

Associate Chief Scientific Officer and Director
Hemostasis, Platelet Immunology & Genomics Laboratory, Bloodworks Northwest
Professor of Medicine/Hematology, University of Washington

Dr. Konkle will contextually discuss 8CHECK, a free F8 gene mutation testing service offered by Octapharma, developed to inform and improve treatment decisions in hemophilia A.

View the on-demand webinar

*Required fields

If you are a human, please do not fill in this field:

By submitting this form, you are consenting to receive future communications from Octapharma and/or your local Octapharma sales representative. Please review our Privacy Policy.


Focused on Improving Patient Care

Octapharma’s commitment to patient care started at the very beginning. Founded in 1983 on the principle of enhancing the lives of patients across the world, Octapharma is focused exclusively on the development and manufacturing of high-quality human proteins to meet the unmet clinical needs of patients, especially those with rare conditions, in hematology, immunotherapy and critical care.

NUW-0645
Indications and Important Safety Information for NUWIQ® [Antihemophilic Factor (Recombinant)].